AstraZeneca (AZN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sachin Jain from Bank ...
By Bhanvi Satija (Reuters) -Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful ...
SAN DIEGO, CA / ACCESSWIRE / January 9, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...
Hosted on MSN4d
AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?AstraZeneca AZN stock has declined 14% in the past three months. A lot of this price decline is due to ongoing investigations ...
Shares of AstraZeneca PLC AZN inched up 0.81% to £107.54 Wednesday, on what proved to be an all-around positive trading ...
Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...
Analysis of AstraZeneca's market potential, including China and IRA impacts, and the importance of key readouts in 2025 for ...
The ADR's fall snapped a three-day winning streak.
IT worker can continue legal battle against pharmaceutical giant after judge rules that impact of skin condition makes him a ...
Finally, the AstraZeneca class action lawsuit alleges that on December 18, 2024, Financial Times published an article ...
"It's fantastic news that olaparib has been approved for use on the NHS in England, providing a second targeted treatment option for certain people with locally advanced or secondary breast cancer who ...
AstraZeneca has been taking a wider role in Vietnam’s healthcare sector to help expand access to quality healthcare.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback